DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Evaluation of Genes Involved in the Duodenal Epithelial Integrity Pre and Post Treatment With Betablockers in Cirrhotics

Information source: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hepatic Cirrhosis

Intervention: Propanolol (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Official(s) and/or principal investigator(s):
Jonathan Manuel Aguirre Valadez, MD, Principal Investigator, Affiliation: INCMNSZ

Overall contact:
Aldo Torre Delgadillo, MD, Phone: 525554870900, Email: detoal@yahoo.com

Summary

The purpose of this study is to compare the expression of genes that produce proteins in intercellular junction duodenal / gastric mucosa in cirrhotic patients (on secondary prophylaxis) before and after treatment with propranolol for 1 month.

Clinical Details

Official title: Evaluation of Genes Involved in the Duodenal Epithelial Integrity, Inflammatory Citosin and Lipopolysaccharide in Cirrhotic Patient Pre and Post Treatment With Non Selective Betablockers (Propanolol)

Study design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Measure of expression of genes (RNAm) related to tight junction proteins in the duodenum

Secondary outcome:

Measure of intestinal permeability (by determinate sugar elimination in urine) pre and posttreatment with propranolol

determinate tight junction proteins by immunohistochemic in the epithelium of the duodenum pre and posttreatment with propranolol

Detailed description: Some complications presented by patients with liver cirrhosis are associated with secondary to increased intestinal permeability and a subsequent increase in pro-inflammatory cytokines bacterial translocation. The use of beta blockers nonselective has it associated with decreased intestinal permeability independently decreased venous gradient hepatic portal, the mechanism by which this permeability decreases has not been established between the proposed mechanisms are: the modification splanchnic hemodynamics, increased gastrointestinal motility and immunological properties of the non-selective beta-blockade; however, it is unknown whether the Beta-Blocker treatment alters the expression of intercellular adhesion proteins such mechanism decreased intestinal permeability.

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Cirrhosis of any ethiology

- Child Pugh A, B, C without beta-blocker treatment previously (min. 1 month without

treatment)

- Patients without big variceal disease or evidence of poor prognosis

- Signing of inform consent

Exclusion Criteria:

- Variceal disease without cirrhosis

- Cirrhotics patients that use antibiotics, prebiotics and probiotics during the study

period and one month previously

- Patients under immunosuppressor treatment

- Patients with active infection process

- Patients with portal thrombosis

- Patients with Sd. Budd-Chiari or cava/suprahepatic thrombosis

Locations and Contacts

Aldo Torre Delgadillo, MD, Phone: 525554870900, Email: detoal@yahoo.com

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City 14000, Mexico; Recruiting
Aldo Torre Delgadillo, M.D. M.Sc, Phone: 54870900, Ext: 2711, Email: detoal@yahoo.com
Aldo Torre-Delgadillo, MD, Principal Investigator
Additional Information

Starting date: May 2015
Last updated: June 24, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017